Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,496.80GBp
19 Sep 2018
Change (% chg)

10.00 (+0.67%)
Prev Close
1,486.80
Open
1,498.40
Day's High
1,505.80
Day's Low
1,479.40
Volume
7,220,362
Avg. Vol
8,022,713
52-wk High
1,634.48
52-wk Low
1,235.20

Summary

Name Age Since Current Position

Philip Hampton

64 2015 Non-Executive Chairman of the Board

Emma Walmsley

48 2017 Chief Executive Officer, Executive Director

Simon Dingemans

54 2011 Chief Financial Officer, Executive Director

Roger Connor

2018 President - Vaccines

Luc Debruyne

2016 President - Global Vaccines

Brian McNamara

50 2016 Chief Executive Officer - GSK Consumer Healthcare

Luke Miels

2017 President - Global Pharmaceuticals

Regis Simard

2018 President - Pharmaceutical Supply Chain

Phil Thomson

2017 President - Global Affairs

Daniel Troy

2008 Senior Vice President, General Counsel

Claire Thomas

2008 Senior Vice President - Human Resources

Nick Hirons

2014 Senior Vice President – Global Ethics and Compliance

Karenann Terrell

2017 Chief Digital & Technology Officer

Hal Barron

55 2018 Chief Scientific Officer, President - Research & Development, Executive Director

David Redfern

51 2008 Chief Strategy Officer

Victoria Whyte

2011 Company Secretary

Roy Anderson

70 2007 Non-Executive Independent Director

Manvinder Banga

63 2016 Senior Non-Executive Independent Director

Vivienne Cox

59 2017 Non-Executive Independent Director

Lynn Elsenhans

61 2012 Non-Executive Independent Director

Laurie Glimcher

66 2017 Non-Executive Independent Director

Jesse Goodman

66 2017 Non-Executive Independent Director

Judy Lewent

69 2011 Non-Executive Independent Director

Urs Rohner

59 2015 Non-Executive Independent Director

Biographies

Name Description

Philip Hampton

Sir Philip Hampton is Non-Executive Chairman of the Board of GlaxoSmithKline PLC., since May 7, 2015. Prior to joining GSK, Philip chaired major FTSE 100 companies, including The Royal Bank of Scotland Group plc and J Sainsbury plc. He has also served as Group Finance Director at Lloyds TSB Group, BT Group plc, BG Group plc, British Gas plc and British Steel plc. Philip was previously appointed an Executive Director of Lazards and a Non-Executive Director of RMC Group Plc and Belgacom SA. Until 2009, he was Chairman of UK Financial Investments Limited, which manages the UK Government’s shareholdings in banks. Philip is the Senior Independent Director of Anglo American Plc, Chairman of its Remuneration Committee and a member of its Audit Committee. Philip is also Chair of the Hampton-Alexander Review on FTSE Women Leaders, an independent review on improving gender balance in FTSE leadership.

Emma Walmsley

Ms. Emma Walmsley is Chief Executive Officer, Executive Director of GlaxoSmithKline PLC. Emma joined GSK in 2010 with responsibility for Consumer Healthcare, Europe and was subsequently appointed President of GlaxoSmithKline Consumer Healthcare in October 2011. She has been a member of GSK’s Corporate Executive Team since 2011 and was appointed CEO of GSK Consumer Healthcare, a joint venture between GSK and Novartis, from its creation in March 2015 until her appointment as GSK CEO Designate in September 2016. Emma joined the GSK Board on 1 January 2017 and succeeded Sir Andrew Witty as GSK CEO on 1 April 2017. Prior to joining GSK, Emma worked with L’Oreal for 17 years where she held a variety of marketing and general management roles in Paris, London and New York. From 2007, she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. Emma was a Non-Executive Director of Diageo plc from 1 January to 21 September 2016. She holds an MA in Classics and Modern Languages from Oxford University.

Simon Dingemans

Mr. Simon Dingemans is no longer Chief Financial Officer, Executive Director of GlaxoSmithKline Plc., effective May 2019. Prior to joining GSK, Simon had over 25 years of experience in investment banking at SG Warburg and Goldman Sachs. Simon advised GSK for over a decade before his appointment and was closely involved in a number of GSK’s key strategic projects. Simon was previously Chairman of the 100 Group of Finance Directors. Prior to joining GSK, Simon had over 25 years of experience in investment banking at SG Warburg and Goldman Sachs. Simon advised GSK for over a decade before his appointment and was closely involved in a number of GSK’s key strategic projects. Simon was previously Chairman of the 100 Group of Finance Directors.

Roger Connor

Mr. Roger Connor is re designated as President - Vaccines of the company effective from 1 September, 2018. He is no longer President - Global Manufacturing & Supply of Glaxosmithkline PLC effective from 1 September, 2018. He joined CET in 2012 and was appointed President, Global Manufacturing & Supply in 2013, after working for a year as President Designate. Prior to this, he was Vice President, Office of the CEO and Corporate Strategy. Roger joined GSK in 1998 from AstraZeneca. He was appointed to the Board of GSK Consumer Healthcare, our joint venture with Novartis, in April 2017. Roger holds a degree in Mechanical and Manufacturing Engineering from Queen’s University Belfast and a Masters in Manufacturing Leadership from Cambridge University. He is a Chartered Accountant.

Luc Debruyne

Mr. Luc Debruyne is no longer President - Global Vaccines of the Company effective end of the 2018. Luc joined CET in 2016 as President, Global Vaccines, a role he has held since 2013. He joined GSK in 1991 as a commercial strategy director in R&D, before leading the European Commercial Centre of Excellence. In 2006, Luc became General Manager in the Netherlands and then in 2010 Senior Vice President and General Manager in Italy. In 2012, he was appointed Senior Vice President, Pharma Europe, prior to his current role. Luc is a member of the International Federation of Pharmaceutical Manufacturers & Associations Vaccines CEO Roundtable and the Management Committee of the Belgian Federation of Enterprises. He holds a Master’s degree in Physical Education from University of Leuven.

Brian McNamara

Mr. Brian McNamara is Chief Executive Officer - GSK Consumer Healthcare of the Company. Brian joined CET in 2016, when he was appointed CEO, GSK Consumer Healthcare. He joined GSK in 2015 as Head of Europe and Americas for GSK Consumer Healthcare, following the creation of a joint venture between GSK and Novartis. Previously, he was head of Novartis’s OTC division. Brian began his career at Procter and Gamble. He is Chairman of the World Self-Medication Industry Association. He earned an undergraduate degree in Electrical Engineering from Union College in New York and an MBA in Finance from the University of Cincinnati.

Luke Miels

Mr. Luke Miels is the President - Global Pharmaceuticals of the Company. Luke joined GSK and CET in September 2017 as President, Global Pharmaceuticals responsible for our commercial portfolio of medicines and vaccines. Previously, he worked for AstraZeneca as Executive Vice President of their European business and, prior to that, Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs. Before then, he held roles of increasing seniority at Roche and Sanofi-Aventis. He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.

Regis Simard

Mr. Regis Simard is appointed as President - Pharmaceutical Supply Chain of the company effect from 1 September 2018. He is currently SVP Global Pharma Manufacturing and joined GSK in 2005 as a site director in France, having previously worked in the electronics, medical devices and pharmaceutical industries.

Phil Thomson

Mr. Phil Thomson serves as President - Global Affairs of the Company. Phil joined CET in 2011. He was appointed President, Global Affairs in April 2017, with specific responsibilities for the Group’s strategic approach to Reputation, Corporate Responsibility, Global Health, China and Britain’s withdrawal from the European Union. He is responsible for our engagement with investors, media, government, key global community partners and employees. Previously, he was Senior Vice President, Communications and Government Affairs. He joined GSK as a commercial trainee in 1996. Phil is Chairman of The Whitehall & Industry Group and a Board Member of the China-Britain Business Council. He earned his degree in English, History and Russian Studies from Durham University.

Daniel Troy

Mr. Daniel E. (Dan) Troy is Senior Vice President, General Counsel of GlaxoSmithKline PLC., since September 2008. Dan joined GSK and CET as Senior Vice President & General Counsel in 2008. He was previously a Partner at the Washington law firm Sidley Austin LLP, where he principally represented pharmaceutical companies and trade associations on matters related to the US Food and Drug Administration (FDA) and government regulations. Dan was formerly Chief Counsel for the FDA. Dan holds a B.S. in Industrial and Labor Relations from Cornell University and a J.D. from Columbia University School of Law. He chairs the US Chamber of Commerce Litigation Center and is a member of the American Law Institute. It was announced in January 2018 that Dan Troy will leave GSK at a later date in 2018 when his role relocates to the UK.

Claire Thomas

Ms. Claire Thomas is Senior Vice President - Human Resources of GlaxoSmithKline PLC., since May 2008. She was appointed to CET as Senior Vice President, Human Resources in 2008. Claire joined the company in 1996 as Senior Manager, Human Resources, Sales and Marketing Group, UK Pharmaceuticals before becoming Director of Human Resources for UK Pharmaceuticals in 1997. She was appointed Senior Vice President, Human Resources, Pharmaceuticals Europe in 2001, and Senior Vice President, Human Resources, Pharmaceuticals International in 2006. Prior to GSK, she worked for Ford Motor Company, holding various positions in Human Resources. Claire has a Bachelor of Science degree in Economics, Management and Industrial Relations from the University of Wales.

Nick Hirons

Mr. Nick Hirons is Senior Vice President – Global Ethics and Compliance of the Company. Nick was appointed to CET in 2014 as Senior Vice President, Global Ethics and Compliance, responsible for compliance, risk management, corporate security and investigations. Nick joined GSK in 1994 as an International Auditor. He was later Head of Audit & Assurance, where he combined five audit functions into an independent team with a common risk-based methodology. In 2013, Nick relocated to China to establish a governance model for our China business that created a consistent approach to compliance. Nick is a fellow of the Chartered Institute of Management Accountants.

Karenann Terrell

Ms. Karenann K. Terrell serves as Chief Digital & Technology Officer of the Company. Karenann joined GSK and CET in September 2017 as Chief Digital & Technology Officer, responsible for our technology, digital, data and analytics strategy. Previously, she worked for Walmart as Chief Information Officer. Prior to this, she was at Baxter International, where she was Chief Information Officer, and before that Daimler Chrysler Corporation. Karenann began her career in General Motors. Karenann is a member of the board of trustees for the New York Hall of Science and in 2017 she became a Non-Executive Director of Pluralsight LLC. She earned graduate and post-graduate degrees in Electrical Engineering from Kettering and Purdue Universities respectively.

Hal Barron

Dr. Hal V. Barron, M.D., serves as Chief Scientific Officer, President - Research & Development, Executive Director of the Company., effective 1 January 2018. Dr Hal was President R&D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to joining Calico, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer. Hal was a Non-Executive Director and Chair of The Science & Technology Committee at Juno Therapeutics, Inc. Hal is Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco.

David Redfern

Mr. David Redfern is Chief Strategy Officer of GlaxoSmithKline PLC. David joined CET as Chief Strategy Officer in 2008 and is responsible for corporate development and strategic planning. Previously, he was Senior Vice President, Northern Europe with responsibility for GSK’s pharmaceutical businesses in that region and, prior to that, was Senior Vice President for Central and Eastern Europe. David joined GSK in 1994. He was appointed Chairman of the Board of ViiV Healthcare Limited in 2011 and a Non- Executive Director of the Aspen Pharmacare Holdings Limited Board in 2015. David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

Victoria Whyte

Ms. Victoria L. Whyte serves as Company Secretary of GlaxoSmithKline PLC., since 1 January 2011. She is a solicitor and a Fellow of the Institute of Chartered Secretaries and Administrators. Victoria was formerly Deputy Secretary and Secretary to the Remuneration Committee. She has acted as Secretary to the Board and all the Board’s Committees since her appointment as Company Secretary on 1 January 2011.

Roy Anderson

Prof. Sir Roy Malcolm Anderson is Non-Executive Independent Director of GlaxoSmithKline Plc., since 1 October 2007. Professor Sir Roy is a world-renowned medical scientist with advanced knowledge of infectious disease epidemiology, and is currently Professor of Infectious Disease in the Faculty of Medicine, Imperial College, London. He is a Fellow of the Royal Society, the Academy of Medical Sciences and the Royal Statistical Society. He is an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the National Academy of Medicine at the US National Academy of Sciences and the French Academy of Sciences. Professor Sir Roy brings scientific expertise to the Board’s deliberations. Professor Sir Roy is a member of the Holdingham International Advisory Board and a member of the Science Advisory Board of the Natural History Museum, London. He is also a member of the Vaccine International Advisory Board (VACCIAB) of AJ Pharma Holding Sdn. Bhd in Malaysia, the International Alzheimer’s Consortium at Harvard University, Boston, Chairman of the Scientific Advisory Board of the Netherlands Centre for One Health (NCOH) and Chairman of Oriole Global Health Ltd.

Manvinder Banga

Mr. Manvinder Singh (Vindi) Banga is Senior Non-Executive Independent Director of the Company since May 5, 2016. Prior to joining GSK, Vindi spent 33 years at Unilever plc, where his last role (amongst several senior positions) was President of the Global Foods, Home and Personal Care businesses, and he was a member of the Unilever Executive Board. Vindi sat on the Prime Minister of India’s Council of Trade & Industry from 2004 to 2014, and was on the Board of Governors of the Indian Institute of Management (IIM), Ahmedabad. Vindi is also the recipient of the Padma Bhushan, one of India’s highest civilian honours. Between 2015 and 2016, Vindi was a Non-Executive Director of Thomson Reuters Corp and a member of its HR committee. Vindi was also previously Chairman of the Supervisory Board of Mauser Group. Vindi is a Partner at private equity investment firm Clayton Dubilier & Rice. He is also Chairman of Kalle GmbH, Senior Independent Director of Marks & Spencer Group plc, a member of its Nomination Committee and Chairman of its Remuneration Committee. Vindi is a Non-Executive Director of the Confederation of British Industry (CBI), a Director of High Ridge Brands Co, a member of the Holdingham International Advisory Board and Chair of the Board of Trustees of Marie Curie. He is also on the Governing Board of the Indian School of Business (ISB), Hyderabad, and is a member of the Indo UK CEO Forum.

Vivienne Cox

Dr. Vivienne Cox, CBE, is Non-Executive Independent Director of the Company. Vivienne has wide experience of business gained in the energy, natural resources and publishing sectors. She also has a deep understanding of regulatory and government relationships. She worked for BP plc for 28 years, in Britain and continental Europe, in posts including Executive Vice President and Chief Executive of BP’s gas, power and renewable business and its alternative energy unit. Vivienne was previously a Non-Executive Director of BG Group plc and Rio Tinto plc and Lead Independent Director at the UK Government’s Department for International Development. Vivienne was appointed Commander of the Order of the British Empire in the 2016 New Year Honours for services to the UK Economy and Sustainability. Vivienne is Senior Independent Director of Pearson plc, a Non- Executive Director of Stena AB and Chairman of the Supervisory Board of Vallourec, a supplier to the energy industry.

Lynn Elsenhans

Ms. Lynn Laverty Elsenhans is Non-Executive Independent Director of GlaxoSmithKline Plc., since 1 July 2012. Lynn has a wealth of experience of running a global business and significant knowledge of the global markets in which GSK operates. She served as Chair, President and Chief Executive Officer of Sunoco Inc from 2009 to 2012. Prior to joining Sunoco in 2008 as President and Chief Executive Officer, Lynn worked for Royal Dutch Shell, which she joined in 1980, and where she held a number of senior roles, including Executive Vice President, Global Manufacturing from 2005 to 2008. Lynn was previously a Non-Executive Director of Flowserve Corporation and The First Tee of Greater Houston. Lynn is a Non-Executive Director of Baker Hughes, a GE company, and Chair of its Audit Committee, and a Director of the Texas Medical Center. She is also a Trustee of the United Way of Greater Houston.

Laurie Glimcher

Dr. Laurie H. Glimcher serves as Non-Executive Independent Director of the Company since 1 September 2017. Dr Laurie is currently Professor of Medicine at Harvard Medical School and is CEO, President and an Attending Physician at the Dana- Farber Cancer Institute. In addition to a number of senior leadership positions held at both Harvard Medical School and Harvard School of Public Health, Laurie has also served as Stephen and Suzanne Weiss Dean and Professor of Medicine at Weill Cornell Medical College and as an Attending Physician at the New York Presbyterian Hospital/Weill Cornell Medical Center. Laurie stepped down from the Board of Bristol- Myers Squibb Co (BMS) in 2017 after serving for 20 years on its Board. Laurie brings scientific and public health expertise to the Board’s deliberations. Laurie is a member of the US National Academy of Sciences and the National Academy of Medicine. She is a member of the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy and a Non-Executive Director of the Waters Corporation, where she also serves on its Corporate Governance Committee. In addition, Laurie is co-founder and Chair of the Scientific Advisory Board of Quentis Therapeutics Inc and a Scientific Advisory Board member of Repare Therapeutics Inc and the American Asthma Foundation.

Jesse Goodman

Dr. Jesse Goodman is Non-Executive Independent Director of the Company since 1 January 2017. Dr Jesse previously served in senior leadership positions at the US Food and Drug Administration (FDA), including most recently as the FDA’s Chief Scientist and previously as Deputy Commissioner for Science and Public Health and as Director of the Center for Biologics Evaluation and Research (CBER). Jesse played a leadership role in developing the FDA’s Regulatory Science and Medical Countermeasures Initiatives and has worked collaboratively with industry, academia, government and global public health and regulatory partners to prepare for and respond to major public health threats, including emerging infectious diseases, disasters and terrorism. He led the FDA’s response to West Nile Virus and to the 2009 H1N1 influenza pandemic and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. Jesse brings scientific and public health expertise to the Board’s deliberations. Jesse, currently Professor of Medicine at Georgetown University, directs the Georgetown University Center on Medical Product Access, Safety and Stewardship (COMPASS) and is an active clinician who serves as Attending Physician in Infectious Diseases. He also serves as President and Member of the Board of the United States Pharmacopeia (USP) and as a member of the Regulatory Working Group of the Coalition for Epidemic Preparedness Innovations (CEPI).

Judy Lewent

Ms. Judy C. Lewent is Non-Executive Independent Director of Glaxosmithkline Plc., since May 8, 2014. Judy has extensive knowledge of the global pharmaceutical industry and of corporate finance, having joined Merck & Co in 1980 and then served as its Chief Financial Officer from 1990 to 2007 when she retired. Judy previously served as a Non-Executive Director of Dell Inc, Quaker Oats Company and Motorola Inc. The Board has determined that Judy has recent and relevant financial experience, and agreed that she has the appropriate qualifications and background to be an audit committee financial expert. Judy is a Non-Executive Director of Thermo Fisher Scientific Inc and Motorola Solutions Inc. She is also a Trustee of the Rockefeller Family Trust, a life member of the Massachusetts Institute of Technology Corporation, a member of the American Academy of Arts and Sciences and a member of the Business Advisory Board of twoXAR.

Urs Rohner

Mr. Urs Rohner is Non-Executive Independent Director of GlaxoSmithKline PLC. Urs has a broad range of business and legal experience having served as Chairman on a number of Boards, most recently for Credit Suisse, a world-leading financial services company. Prior to joining Credit Suisse in 2004, Urs served as Chairman of the Executive Board and CEO of ProSieben and ProSiebenSat.1 Media AG. This followed a number of years in private practice at major law firms in Switzerland and the US, having been admitted to the bars of the canton of Zurich in Switzerland in 1986 and the state of New York in the US in 1990. Urs is currently Chairman of the Board of Credit Suisse Group AG and of its Chairman’s and Governance Committee. He is also Chairman and member of the Board of Trustees of Credit Suisse Research Institute and Credit Suisse Foundation. Urs was appointed Vice-Chairman of the Governing Board of the Swiss Bankers Association in 2015.